Pre-made Vudalimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-CTLA4/CTLA-4;PDCD1/PD-1 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-631
Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor's proprietary XmAb® technology) that increases binding affinity to the receptor FcRn.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody|
|Format||Bispecific Mixed mAb and scFv|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None|
|Conditions Active||Solid tumours|